Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dimethylformamide SCHEMBL7942578 | 1.00 | TSHR (0.47) | TSHRCA2CYP3A4USP2ALOX15 | |
| Dimethylformamide SCHEMBL28253639 | 1.00 | TSHR (0.47) | TSHRCA2CYP3A4USP2ALOX15 | |
| Dimethylformamide SCHEMBL2530045 | 0.92 | TSHR (0.56) | TSHRCA2USP2ALOX15PIK3CD | |
| Dimethylformamide SCHEMBL28261531 | 0.89 | MEN1 (0.46) | TSHRCA2USP2ALOX15 | |
| Triethylene Glycol SCHEMBL9487295 | 0.89 | MEN1 (0.46) | TSHRCA2USP2ALOX15 | |
| Dimethylformamide SCHEMBL14813149 | 0.82 | TSHR (0.45) | TSHRUSP2ALOX15 | |
| Dimethylformamide SCHEMBL4939650 | 0.80 | TSHR (0.43) | TSHRUSP2ALOX15 | |
| Dimethylformamide SCHEMBL10802383 | 0.79 | TSHR (0.47) | TSHRCYP3A4ALOX15 | |
| SCHEMBL8745522 | 0.78 | CA2 (0.34) | CA2 | |
| SCHEMBL28102916 | 0.78 | CA2 (0.34) | TSHRCA2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1490390-A2 | C-17 SPIROLACTONIZATION AND 6,7 OXIDATION OF STEROIDS | Pharmacia Corporation (US) | 2004-12-29 | — | — | EP | claimed |
| US-20040024202-A1 | C-17 spirolactonization and 6,7 oxidation of steroids | PHARMACIA CORPORATION | 2004-02-05 | — | — | US | claimed |
| WO-2003082894-A2 | C-17 SPIROLACTONIZATION AND 6,7 OXIDATION OF STEROIDS | PHARMACIA CORPORATION (US) | 2003-10-09 | — | — | WO | claimed |
| CN-110392724-A | Mixture containing perovskite compound | 住友化学株式会社 | 2019-10-29 | — | — | CN | disclosed |
| CN-109275335-B | The manufacturing method of composition and composition | 住友化学株式会社 | 2019-10-15 | — | — | CN | disclosed |
| CN-110114441-A | Composition, film, laminate structure, light emitting device and display | 住友化学株式会社 | 2019-08-09 | — | — | CN | disclosed |
| CN-110088229-A | Composition comprising a metal oxide and a metal oxide | 住友化学株式会社 | 2019-08-02 | — | — | CN | disclosed |
| CN-110088230-A | COMPOSITION, FILM, LAMINATED STRUCTURE, LIGHT-EMITTING DEVICE, DISPLAY, AND METHOD FOR PRODUCING COMPOSITION | 住友化学株式会社 | 2019-08-02 | — | — | CN | disclosed |
| CN-110088231-A | Composition, film, laminate structure, light emitting device and display | 住友化学株式会社 | 2019-08-02 | — | — | CN | disclosed |
| CN-110088232-A | Composition, film, laminate structure, light emitting device and display | 住友化学株式会社 | 2019-08-02 | — | — | CN | disclosed |
| CN-109328178-A | Composition comprising a metal oxide and a metal oxide | 住友化学株式会社 | 2019-02-12 | — | — | CN | disclosed |
| CN-109311691-A | Compound, dispersion composition, and resin composition | 住友化学株式会社 | 2019-02-05 | — | — | CN | disclosed |
| CN-109311692-A | Composition and compound | 住友化学株式会社 | 2019-02-05 | — | — | CN | disclosed |
| CN-109275335-A | The manufacturing method of composition and composition | 住友化学株式会社 | 2019-01-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040024202-A1 | C-17 spirolactonization and 6,7 oxidation of steroids | HSD17B7, NR3C2, HSD17B13 | TSHR 2395/4885CA2 1896/4885CYP3A4 118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.